Respivant Sciences Inc.   Report issue

For profit Phase 2
Founded: San Diego CA United States (2018)
Status: Acquired by Roivant Sciences, Inc. (2018) → now Sumitomo Dainippon (2005)

Organization Overview

First Clinical Trial
2019
NCT03864328
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Respivant Sciences GmbH | Respivant Sciences Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

cromoglicic acid (Intal) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cough (Phase 2)

Premature Birth (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1